107 filings
Page 4 of 6
DEF 14A
ol155xo9qmqfp
2 Sep 22
Definitive proxy
8:30am
EFFECT
5jp iyze66
15 Aug 22
Notice of effectiveness
12:15am
CORRESP
x5hucn 280x
10 Aug 22
Correspondence with SEC
12:00am
UPLOAD
gfr3h0ftvuft1t91c
9 Aug 22
Letter from SEC
12:00am
S-3
xos5cyrckg21xam
5 Aug 22
Shelf registration
5:08pm
8-K
f3itb 9lwscqiyy1
5 Aug 22
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
by77698d9or31
1 Aug 22
Candel Therapeutics Appoints Three New Members to its Board of Directors
6:09am
8-K
b25un
6 Jun 22
Regulation FD Disclosure
8:37am
8-K
p7m2cy hdkp6xcr9
26 May 22
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
5:36pm
8-K
95yy41j7nlpdtbd9p9
12 May 22
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
8:15am
S-8
rvr3z
29 Mar 22
Registration of securities for employees
5:28pm
10-K
ry0k7d3
29 Mar 22
Annual report
8:46am
8-K
yd0vgpdz1zdkoxjel
29 Mar 22
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
8:32am
8-K
pdc577o hz5c9
1 Mar 22
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
8:09am
8-K
n72zqqf0c1nwhm9v0i
9 Feb 22
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
8:05am
8-K
p1j4u13
31 Jan 22
Departure of Directors or Certain Officers
8:30am
8-K
0k9kvdoqe5
12 Nov 21
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
8:11am